Editas Medicine, Inc. (EDIT)

10,77 +0,24 (+2,28%) Alla chiusura: 04:00PM EST

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000
https://www.editasmedicine.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 226

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Gilmore O'Neill	President, CEO & Director	815,37k	N/D	1964
Dr. Bruce E. Eaton Ph.D.	Executive VP, CTO & Chief Business Officer	786,23k	N/D	1954
Dr. Baisong Mei M.D., Ph.D.	Senior VP & Chief Medical Officer	386,99k	N/D	N/D
Dr. Feng Zhang Ph.D.	Co-Founder & Scientific Advisory Board Member	N/D	N/D	N/D
Dr. George McDonald Church Ph.D.	Co-Founder & Scientific Advisory Board Member	N/D	N/D	1954
Dr. J. Keith Joung M.D., Ph.D.	Co-Founder & Scientific Advisory Board Member	N/D	N/D	N/D
Dr. David R. Liu Ph.D.	Co-Founder & Scientific Advisory Board Member	N/D	N/D	N/D
Mr. Erick J. Lucera C.F.A., CPA	CFO & Executive VP	N/D	N/D	1968
Mr. Harry R. Gill III	Senior Vice President of Operations	N/D	N/D	1961
Dr. Linda C. Burkly Ph.D.	Executive VP & Chief Scientific Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Editas Medicine, Inc. al 28 novembre 2023 è 6. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 4; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.